Revance ups IPO, gets $96M for topical form of Botox in phase III
By Randy Osborne
Thursday, February 6, 2014
Topical Botox developer Revance Therapeutics Inc. priced its initial public offering (IPO) at the top of the projected range, sold more shares than expected and came out of the gate strong, with the stock (NASDAQ:RVNC) closing Thursday at $26.85, up $10.85, or 67.8 percent.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.